In preclinical models of ALK-positive ALCL, Drakos et al. have shown that p53 reactivation by the MDM2 inhibitor nutlin-3a increased p53 concentration, enhanced apoptosis, and decreased tumorigenicity [104]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.